LSTA vs. KFFB, LUMO, ORGS, OTRK, NEOS, ASRT, TLSA, CNTB, ETON, and ORMP
Should you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Kentucky First Federal Bancorp (KFFB), Lumos Pharma (LUMO), Orgenesis (ORGS), Ontrak (OTRK), Neos Therapeutics (NEOS), Assertio (ASRT), Tiziana Life Sciences (TLSA), Connect Biopharma (CNTB), Eton Pharmaceuticals (ETON), and Oramed Pharmaceuticals (ORMP).
Lisata Therapeutics (NASDAQ:LSTA) and Kentucky First Federal Bancorp (NASDAQ:KFFB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
In the previous week, Kentucky First Federal Bancorp had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Kentucky First Federal Bancorp and 3 mentions for Lisata Therapeutics. Kentucky First Federal Bancorp's average media sentiment score of 0.67 beat Lisata Therapeutics' score of 0.29 indicating that Kentucky First Federal Bancorp is being referred to more favorably in the news media.
Lisata Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Kentucky First Federal Bancorp has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.
Kentucky First Federal Bancorp received 77 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Lisata Therapeutics an outperform vote while only 60.00% of users gave Kentucky First Federal Bancorp an outperform vote.
Lisata Therapeutics has a net margin of 0.00% compared to Kentucky First Federal Bancorp's net margin of -3.85%. Kentucky First Federal Bancorp's return on equity of -1.21% beat Lisata Therapeutics' return on equity.
Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 410.20%. Given Lisata Therapeutics' higher possible upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Kentucky First Federal Bancorp.
Kentucky First Federal Bancorp has higher revenue and earnings than Lisata Therapeutics. Kentucky First Federal Bancorp is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Kentucky First Federal Bancorp shares are owned by institutional investors. 21.6% of Lisata Therapeutics shares are owned by insiders. Comparatively, 5.3% of Kentucky First Federal Bancorp shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Lisata Therapeutics and Kentucky First Federal Bancorp tied by winning 8 of the 16 factors compared between the two stocks.
Get Lisata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lisata Therapeutics Competitors List
Related Companies and Tools
